EUVIMEDEUVIMED entdecken
Crossref

A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV)

D'Andrea K. Joseph, Gerard A. Baltazar, Ricardo A. Jacquez, Shahidul Islam, Adam Stright, Jasmin Divers, Collin E.M. Brathwaite, Patrizio Petrone

Innovations in Surgery and Interventional Medicine · 2021

DOI: 10.36401/isim-20-03 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovations in Surgery and Interventional Medicine, 2021. Verfasst von D'Andrea K. Joseph und 7 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pneumonia leading to acute respiratory distress syndrome (ARDS) is one of the devastating consequences of coronavirus disease 2019 (COVID-19). Airway pressure release ventilation (APRV) has been described as beneficial in acute lung injury and ARDS. We hypothesized that utilizing APRV would be advantageous in the COVID-19 ARDS population.

Methods

Prospective, observational, single-center study. Data were extracted on demographics, vasopressors, sedatives, analgesics, and oxygenation (PaO2/FiO2). A generalized linear mixed models analysis was performed to compare low tidal volume ventilation (LTV) with APRV for patients who required intubation due to ARDS from COVID-19 and who were managed with at least 48 consecutive hours of APRV in our surgical intensive care unit (SICU).

Results

Twelve patients met criteria; two were on APRV mode from admission to the SICU and were not included in the study. Ten patients were analyzed and were primarily male (70%), average age of 64.5 ± 12.9 years, and 70% were obese (average body mass index of 30.6 ± 8.0 kg/m2). There were no smokers in the sample, but two patients presented with underlying lung pathology. APRV was shown to significantly increase the PaO2/FiO2 ratio by 30% (5% to 61%) (p = 0.05) and was associated with up to a 12% (−26% to 5%) reduction in the level of FiO2 and reduction in the use of vasopressor support (−59% [−83% to −2%]), sedatives (−15% [−29% to 2%]), and analgesics (−16% [−38% to 12%]).

Conclusions

This pilot study showed that APRV was associated with decreases in FiO2, vasopressors, sedatives, and analgesic requirements with an increase in PaO2/FiO2 ratio. In the current pandemic, where providers are grappling with ways to manage COVID-19 ARDS, APRV may be the optimal ventilator mode. Prospective randomized studies are required to validate whether use of APRV in the COVID-19 population leads to improved oxygenation and a subsequent decrease of ventilator days and length of stay.

Zitieren

APA

Joseph, D. K., Baltazar, G. A., Jacquez, R. A., Islam, S., Stright, A., Divers, J., Brathwaite, C. E., & Petrone, P. (2021). A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV). Innovations in Surgery and Interventional Medicine. https://doi.org/10.36401/isim-20-03

Vancouver

Joseph DK, Baltazar GA, Jacquez RA, Islam S, Stright A, Divers J, et al. A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV). Innovations in Surgery and Interventional Medicine. 2021. doi:10.36401/isim-20-03

BibTeX
@article{Joseph2021,
  author = {Joseph, D'Andrea K. and Baltazar, Gerard A. and Jacquez, Ricardo A. and Islam, Shahidul and Stright, Adam and Divers, Jasmin and Brathwaite, Collin E.M. and Petrone, Patrizio},
  title = {A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV)},
  journal = {Innovations in Surgery and Interventional Medicine},
  year = {2021},
  doi = {10.36401/isim-20-03}
}
Kostenlos starten →